Palleon Pharmaceuticals
Biotechnology, 266 Second Ave, Waltham, Massachusetts, 02451, United States, 11-50 Employees
Phone Number: 85********
Who is PALLEON PHARMACEUTICALS
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The companys proprietary Convergence Platform integr...
Read More
-
Headquarters: 266 Second Ave, Waltham, Massachusetts, 02451, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from PALLEON PHARMACEUTICALS
Palleon Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Palleon Pharmaceuticals
Answer: Palleon Pharmaceuticals's headquarters are located at 266 Second Ave, Waltham, Massachusetts, 02451, United States
Answer: Palleon Pharmaceuticals's phone number is 85********
Answer: Palleon Pharmaceuticals's official website is https://palleonpharma.com
Answer: Palleon Pharmaceuticals's revenue is $25 Million to $50 Million
Answer: Palleon Pharmaceuticals's SIC: 2834
Answer: Palleon Pharmaceuticals's NAICS: 541714
Answer: Palleon Pharmaceuticals has 11-50 employees
Answer: Palleon Pharmaceuticals is in Biotechnology
Answer: Palleon Pharmaceuticals contact info: Phone number: 85******** Website: https://palleonpharma.com
Answer: Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The companys proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month